Health

OpenAI makes UK startup Anima its healthcare showcase as patients call the same bot a wall to care

OpenAI's October 23 customer story hands UK startup Anima a vendor endorsement just as it enters the US and Australia. The 75% wait cut is Anima's own measurement, and this month Wantage patients called the same bot a wall to care.

Vincent JiangVincent Jiang · 2 min read
Share
Sam Altman speaking on a panel
OpenAI chief executive Sam Altman. His company made Anima, the UK startup behind the NHS receptionist bot Andi, its healthcare customer story on October 23, 2026.

Earlier this month, patients at Newbury Street Practice in Wantage, England, called the AI receptionist Andi a "wall" to care; the bot asked one 65-year-old whether she was phoning about her pregnancy 1. On October 23, OpenAI$500B — OpenAI, private, latest valuation $500B made Andi's maker, UK startup Anima, a healthcare customer story spanning more than 1,000 clinics and about 14 million patients 2.

The endorsement doubles as distribution

The figures are the pitch. Clinics on Andi, built on GPT-Live, cut phone waits from 40 to 50 minutes to about 10, at least 75%, and median case resolution runs about 3.5 hours across 800,000-plus cases a month 2. Shun Pang, a Cambridge-trained doctor who co-founded Anima 3, says OpenAI won a benchmark of open and closed models on "superior intelligence, intelligence per dollar" 2. The endorsement lands as Anima expands into the US and Australia 2.

Every number is Anima counting itself

Every metric is Anima's own measurement, relayed by its model vendor, and no independent test has confirmed the wait-time claims 4. Anima's own website markets harder than the case study, advertising a greater than 90% cut in phone waits 5. OpenAI's healthcare showcase is a customer grading its own homework.

Receipts and counter-receipts

Document throughput roughly tripled: practices that filed about 15 clinical documents an hour now handle 30 to 45, top performers 45 to 60, and some clinics cleared backlogs above 100,000 documents within days 2.

Document throughput tripled at clinics on Anima, by Anima's own count

  • Estimate
0 docs/hr20 docs/hr40 docs/hr60 docs/hrBefore Anima15 docs/hrTypical with Anima30–45 docs/hrTop performers45–60 docs/hr
Data
ValueRange
Before Anima15 docs/hr—
Typical with Anima (estimate)37.5 docs/hr30–45 docs/hr
Top performers (estimate)52.5 docs/hr45–60 docs/hr
Documents per hour, self-reported by Anima in OpenAI's customer story of October 23, 2026; typical and top bars plot midpoints of the reported ranges (30 to 45 and 45 to 60).2

The Wantage surgery logged more than 11,000 requests, about 180 a working day, with over 60% of booked appointments same-day; feedback ran 79% positive the first month, 84% the second, and the practice says the service passed NHS assurance checks 1. Anima's surveys put would-reuse at 86%, with people in their 80s and 90s among the happiest users 2. One named patient still queued 20 minutes after Andi decided it could not help her 1.

Where the money sits

Anima's last disclosed round is a $12 million Series A of March 2024, led by Molten Ventures with Hummingbird Ventures, Amino Collective and Y Combinator, raised when it served 150 NHS clinics 3. accuRx had raised £36.6 million, Memora Health $80.5 million, NexHealth $177.2 million 3. The case study closes none of that funding gap, but it puts OpenAI's logo on the benchmark every rival now sells against.

Rivals had raised several times Anima's $12 million Series A

$0M$50M$100M$150M$200MAnima$12MMemora Health$80.5MNexHealth$177.2M
Data
Value
Anima$12M
Memora Health$80.5M
NexHealth$177.2M
Disclosed funding as of TechCrunch's March 20, 2024 report, the source of every figure in this section; accuRx's £36.6 million is excluded as a different currency.3

The two readings that decide it

No independent verification exists yet 4. Until one lands, watch Wantage's monthly feedback, which tests whether the wall gets taller, and Anima's next disclosed round, which prices what the endorsement is worth.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Butterfly Network's record quarter ran on milestone money, and its own Q4 guide says so

    Butterfly Network beat every mark this morning, but the filings show the growth came from chip licensing, not the probe business, and the company's own fourth-quarter guide says that money does not repeat. At 17.6 times sales, the market is paying subscription prices for milestone money.

    Health

    GE HealthCare beat and raised, then filed the exit of the PCS chief to a rival's top job

    The same 8-K filed October 28, 2026, carried a quarter strong enough to raise guidance and the resignation of Jeannette Bankes, who leaves the Patient Care Solutions segment five days after its margin jumped 480 basis points. Investors have to price both at once.

    Health

    Eli Lilly's retatrutide beat Ozempic head-to-head: 20.9% weight loss vs 9.4%, before Novo Nordisk reports

    Lilly's retatrutide beat Ozempic's highest approved dose on blood sugar and cut more than twice the weight in a 1,298-patient Phase 3, published two days before Lilly's Q3 report. Novo's flagship franchise just lost its standard-of-care argument inside the window where payers and investors are repricing it.

    Health

    Bunsen now runs 80% of Schrödinger's own modeling jobs, and November 4 shows if customers pay for it

    Schrödinger's Bunsen agent now runs roughly 80 percent of the computational jobs on the company's own cluster, a reversal for a CEO who called AI drug discovery nonsense in 2024. With full launch due by year-end and Q3 results on Nov. 4, the throughput-licensing model is about to be tested on customers, not just insiders.

    Health

    IQVIA's guidance raise leans on unclosed acquisitions, and $2.1 billion of inactive trials left its backlog

    The beat was clean, but the guidance raise leans on acquisitions still to close and $2.1 billion of inactive trials quietly left the backlog. The 400 AI agents are the more interesting number, and December 1 is where the split gets priced.

    Health

    Globus Medical previews an implant designed in software and placed by its robot, Q3 due November 5

    FDA-cleared but not yet for sale, SCRIPT was previewed at NASS on October 14; its plans import straight into the ExcelsiusGPS robot. With Q3 results due November 5, the earnings test is whether US spine keeps taking share while the robotics business works through its leasing shift.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.